MK-677 (Ibutamoren Mesylate)

What is MK-677?

MK-677 (known chemically as Ibutamoren, Ibutamoren Mesylate, or MK-0677) is a potent, non-peptide, orally active growth hormone secretagogue (GHS) that functions as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a, or ghrelin receptor). Originally developed by Merck for metabolic conditions, sarcopenia, and somatotropic deficiencies, MK-677 mimics the action of endogenous ghrelin in the hypothalamus and anterior pituitary gland. Researchers investigate this compound primarily for its ability to induce sustained, pulsatile elevations in circulating growth hormone (GH) and insulin-like growth factor 1 (IGF-1) without requiring frequent subcutaneous injections.

For laboratory and in vitro evaluation, researchers often choose to buy MK-677 in high-purity oral capsule or solution formats. Oral presentations exhibit high systemic bioavailability, eliminating the need for complex reconstitution protocols or specialized reconstitution solution compounding prior to experimental administration.

Chemical and Molecular Data

What are the Mechanisms of Action?

The biochemical pathways and cellular targets of MK-677 include:

• GHS-R1a Ghrelin Receptor Agonism: Research demonstrates that MK-677 binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a) in the central nervous system. This binding activates intracellular signaling cascades that trigger the amplification and release of natural growth hormone pulses from pituitary somatotropes.
• Endogenous GH & IGF-1 Axis Activation: In addition to acute GH release, prolonged administration leads to a sustained, dose-dependent elevation of circulating insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP-3). Crucially, while early doses generate a brief, transient increase in cortisol and prolactin, these stress markers normalize during multi-week trials.
• Anabolic Nitrogen Retention & Bone Remodeling: Studies indicate that elevated systemic IGF-1 levels downstream of GHS-R activation reverse protein catabolism, promote positive nitrogen balance in skeletal muscle tissue, and stimulate osteoblast activity, increasing biochemical markers of bone remodeling.

What are the Clinical & Preclinical Trials on MK-677?

When evaluating research efficacy and published experimental literature for MK-677:

• Controlled Clinical Trial: A double-blind, randomized controlled clinical trial published in PubMed (PMID: 9467542) evaluated obese subjects receiving 25mg daily for 8 weeks. Results confirmed a significant, sustained 40% increase in serum IGF-1 and a statistically significant expansion of fat-free mass (FFM) and basal metabolic rate compared to placebo controls.
• REM Sleep Architecture Enhancement: Double-blind crossover clinical trials detailed in PubMed (PMID: 9349662) investigated the somnogenic impact of MK-677 dosing. Treatment yielded a 50% increase in Stage IV slow-wave sleep duration and a >20% increase in total REM sleep, alongside a significant decrease in night-time sleep deviations in both young and elderly research cohorts.
• Bone Mineral Turnover Assays: Multi-center clinical studies cataloged in PubMed (PMID: 10404019) evaluated elderly subjects over 9 weeks. Daily administration increased serum osteocalcin by 29.4% and bone-specific alkaline phosphatase (BSAP) by 10.4%, confirming a direct stimulation of bone turnover markers. Comprehensive safety reviews indexed in PMC (PMC5632578) document a favorable tolerability profile across human trials.

How does MK-677 compare to other compounds?

To evaluate delivery convenience, biological half-life, and pathway specificity, researchers compare MK-677 against short-acting peptide secretagogues and selective androgen receptor modulators: